Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

LSKL, Inhibitor of Thrombospondin TSP-1 2TFA

🥰Excellent
Catalog No. T7676

LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .

LSKL, Inhibitor of Thrombospondin TSP-1 2TFA

LSKL, Inhibitor of Thrombospondin TSP-1 2TFA

🥰Excellent
Catalog No. T7676
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .
Pack SizePriceAvailabilityQuantity
2 mg$37In Stock
5 mg$52In Stock
10 mg$81In Stock
25 mg$148In Stock
50 mg$229In Stock
100 mg$352In Stock
200 mg$492In Stock
1 mL x 10 mM (in DMSO)$89In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "LSKL, Inhibitor of Thrombospondin TSP-1 2TFA"

Select Batch
Purity:≥98%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .
In vivo
Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight.?Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations.?In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy.?However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy
Animal Research
Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy.
Chemical Properties
Molecular Weight686.64
FormulaC25H44F6N6O9
SmilesCC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CC(C)C)=O)=O)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 27.5 mg/mL (40.05 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.4564 mL7.2818 mL14.5637 mL72.8184 mL
5 mM0.2913 mL1.4564 mL2.9127 mL14.5637 mL
10 mM0.1456 mL0.7282 mL1.4564 mL7.2818 mL
20 mM0.0728 mL0.3641 mL0.7282 mL3.6409 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | purchase LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA cost | order LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA chemical structure | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA in vivo | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA formula | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA molecular weight